Development of oral RA treatments, heated by Korean companies’ patent suits

Development of the Pfizer Pharmaceuticals Korea’s oral rheumatoid arthritis(RA) treatment Xeljanz(generic name: tofacitinib) has been heated.

According to the Intellectual Property Tribunal, the total 12 pharmaceutical companies prepared to enter the market by filing patent lawsuits to avoid Xeljanz’s substance and composition patents on two days between the 20^th and 21^st.

The 12 companies, s...